Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of nemolizumab in prurigo nodularis
NL-OMON54290Phase 3Recruiting
- Sponsor
- Galderma
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nemolizumab in prurigo nodularis (PN) (2 arms), sponsored by Galderma. Primary endpoint: Incidence and severity of adverse events. Started Jul 2021; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NL-OMON54290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54290.